Literature DB >> 30635090

Cancer Immunosurveillance by T Cells.

Samhita Rao1, Karim Gharib1, Arnold Han1.   

Abstract

Cancer immunotherapy is based on the ability of the immune system to recognize tumors as foreign tissue. The idea of cancer immunosurveillance was first conceived over a century ago but remained controversial through much of the 20th century. In the past few decades, however, the field has progressed rapidly, and the concept of tumor immunosurveillance is now well established. With this chapter, we provide a historical background of immunosurveillance, the concept of immunoediting, and the role of different T-cell subsets in the tumor microenvironment. We also discuss the relationship between immune checkpoints, tumor antigens, T cell receptor repertoire, and immunosurveillance. Finally, we comment on the future of immunotherapy as it relates to T cell immunosurveillance.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antigen specificity; Cancer immunosurveillance; Immune checkpoint blockade; Immunoediting; T cell repertoire fitness

Year:  2018        PMID: 30635090     DOI: 10.1016/bs.ircmb.2018.08.001

Source DB:  PubMed          Journal:  Int Rev Cell Mol Biol        ISSN: 1937-6448            Impact factor:   6.813


  15 in total

Review 1.  Trial watch: dendritic cell vaccination for cancer immunotherapy.

Authors:  Jenny Sprooten; Jolien Ceusters; An Coosemans; Patrizia Agostinis; Steven De Vleeschouwer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2019-07-18       Impact factor: 8.110

Review 2.  Autophagy in major human diseases.

Authors:  Daniel J Klionsky; Giulia Petroni; Ravi K Amaravadi; Eric H Baehrecke; Andrea Ballabio; Patricia Boya; José Manuel Bravo-San Pedro; Ken Cadwell; Francesco Cecconi; Augustine M K Choi; Mary E Choi; Charleen T Chu; Patrice Codogno; Maria Isabel Colombo; Ana Maria Cuervo; Vojo Deretic; Ivan Dikic; Zvulun Elazar; Eeva-Liisa Eskelinen; Gian Maria Fimia; David A Gewirtz; Douglas R Green; Malene Hansen; Marja Jäättelä; Terje Johansen; Gábor Juhász; Vassiliki Karantza; Claudine Kraft; Guido Kroemer; Nicholas T Ktistakis; Sharad Kumar; Carlos Lopez-Otin; Kay F Macleod; Frank Madeo; Jennifer Martinez; Alicia Meléndez; Noboru Mizushima; Christian Münz; Josef M Penninger; Rushika M Perera; Mauro Piacentini; Fulvio Reggiori; David C Rubinsztein; Kevin M Ryan; Junichi Sadoshima; Laura Santambrogio; Luca Scorrano; Hans-Uwe Simon; Anna Katharina Simon; Anne Simonsen; Alexandra Stolz; Nektarios Tavernarakis; Sharon A Tooze; Tamotsu Yoshimori; Junying Yuan; Zhenyu Yue; Qing Zhong; Lorenzo Galluzzi; Federico Pietrocola
Journal:  EMBO J       Date:  2021-08-30       Impact factor: 14.012

Review 3.  Organized immune cell interactions within tumors sustain a productive T-cell response.

Authors:  Maria A Cardenas; Nataliya Prokhnevska; Haydn T Kissick
Journal:  Int Immunol       Date:  2021-01-01       Impact factor: 4.823

Review 4.  Controlling Cytokine Release Syndrome to Harness the Full Potential of CAR-Based Cellular Therapy.

Authors:  Monica S Thakar; Tyce J Kearl; Subramaniam Malarkannan
Journal:  Front Oncol       Date:  2020-01-31       Impact factor: 6.244

5.  Immunology of Cell Death in Cancer Immunotherapy.

Authors:  Lorenzo Galluzzi; Abhishek D Garg
Journal:  Cells       Date:  2021-05-15       Impact factor: 6.600

Review 6.  ATP and cancer immunosurveillance.

Authors:  Oliver Kepp; Lucillia Bezu; Takahiro Yamazaki; Francesco Di Virgilio; Mark J Smyth; Guido Kroemer; Lorenzo Galluzzi
Journal:  EMBO J       Date:  2021-06-14       Impact factor: 14.012

Review 7.  Trial watch: STING agonists in cancer therapy.

Authors:  Julie Le Naour; Laurence Zitvogel; Lorenzo Galluzzi; Erika Vacchelli; Guido Kroemer
Journal:  Oncoimmunology       Date:  2020-06-16       Impact factor: 8.110

Review 8.  Detection of immunogenic cell death and its relevance for cancer therapy.

Authors:  Jitka Fucikova; Oliver Kepp; Lenka Kasikova; Giulia Petroni; Takahiro Yamazaki; Peng Liu; Liwei Zhao; Radek Spisek; Guido Kroemer; Lorenzo Galluzzi
Journal:  Cell Death Dis       Date:  2020-11-26       Impact factor: 8.469

Review 9.  Trial watch: IDO inhibitors in cancer therapy.

Authors:  Julie Le Naour; Lorenzo Galluzzi; Laurence Zitvogel; Guido Kroemer; Erika Vacchelli
Journal:  Oncoimmunology       Date:  2020-06-14       Impact factor: 8.110

Review 10.  Calreticulin and cancer.

Authors:  Jitka Fucikova; Radek Spisek; Guido Kroemer; Lorenzo Galluzzi
Journal:  Cell Res       Date:  2020-07-30       Impact factor: 25.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.